09779116 Page 1

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1613SXW

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
* * * * * * * * *
                          Welcome to STN International
                      Web Page URLs for STN Seminar Schedule - N. America
 NEWS 1
 NEWS
        2 Dec 17
                     The CA Lexicon available in the CAPLUS and CA files
 NEWS 3 Feb 06 Engineering Information Encompass files have new names
 NEWS 4 Feb 16 TOXLINE no longer being updated
 NEWS 5 Apr 23 Search Derwent WPINDEX by chemical structure
 NEWS 6 Apr 23 PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
 NEWS 7 May 07 DGENE Reload
 NEWS 8 Jun 20 Published patent applications (A1) are now in USPATFULL
 NEWS 9 JUL 13 New SDI alert frequency now available in Derwent's
                      DWPI and DPCI
NEWS 10 Aug 23 In-process records and more frequent updates now in
                      MEDLINE
NEWS 11 Aug 23
                     PAGE IMAGES FOR 1947-1966 RECORDS IN CAPLUS AND CA
 NEWS 12 Aug 23
                     Adis Newsletters (ADISNEWS) now available on STN
NEWS 13 Sep 17
                     IMSworld Pharmaceutical Company Directory name change
                      to PHARMASEARCH
NEWS 14 Oct 09 Korean abstracts now included in Derwent World Patents
                      Index
NEWS 15 Oct 09 Number of Derwent World Patents Index updates increased
NEWS 16 Oct 15 Calculated properties now in the REGISTRY/ZREGISTRY File
NEWS 17 Oct 22 Over 1 million reactions added to CASREACT
NEWS 18 Oct 22 DGENE GETSIM has been improved
NEWS 19 Oct 29 AAASD no longer available
NEWS 19 Oct 29 AAASD no longer available
NEWS 20 Nov 19 New Search Capabilities USPATFULL and USPAT2
NEWS 21 Nov 19 TOXCENTER(SM) - new toxicology file now available on STN
NEWS 22 Nov 29 COPPERLIT now available on STN
NEWS 23 Nov 29 DWPI revisions to NTIS and US Provisional Numbers
NEWS 24 Nov 30 Files VETU and VETB to have open access
NEWS 25 Dec 10 WPINDEX/WPIDS/WPIX New and Revised Manual Codes for 2002
NEWS 26 Dec 10 DGENE BLAST Homology Search
NEWS 27 Dec 17 WELDASEARCH now available on STN
NEWS 28 Dec 17 STANDARDS now available on STN
NEWS 29 Dec 17 New fields for DBCI
           Dec 17 New fields for DPCI
NEWS 29
NEWS 30 Dec 19 CAS Roles modified
NEWS 31 Dec 19 1907-1946 data and page images added to CA and CAplus
NEWS EXPRESS August 15 CURRENT WINDOWS VERSION IS V6.0c,
                  CURRENT MACINTOSH VERSION IS V6.0 (ENG) AND V6.0J (JP),
                  AND CURRENT DISCOVER FILE IS DATED 07 AUGUST 2001
                  STN Operating Hours Plus Help Desk Availability
NEWS HOURS
NEWS INTER
                 General Internet Information
NEWS LOGIN
                 Welcome Banner and News Items
NEWS PHONE
                 Direct Dial and Telecommunication Network Access to STN
                 CAS World Wide Web Site (general information)
NEWS WWW
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 14:17:00 ON 15 JAN 2002

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION
0.15 0.15

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 14:17:09 ON 15 JAN 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 14 JAN 2002 HIGHEST RN 383122-99-4 DICTIONARY FILE UPDATES: 14 JAN 2002 HIGHEST RN 383122-99-4

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details: http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 779116b.str

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS
L1 STR

0

ОН

Ν

0

Structure attributes must be viewed using STN Express query preparation.

=> s 11 sss sam

SAMPLE SEARCH INITIATED 14:17:49 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 12904 TO ITERATE

7.7% PROCESSED 1000 ITERATIONS INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED) SEARCH TIME: 00.00.03

2 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS:

251289 TO 264871

PROJECTED ANSWERS:

212 TO 820

2 SEA SSS SAM L1

=> s 11 full

FULL SEARCH INITIATED 14:17:57 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED - 260128 TO ITERATE

100.0% PROCESSED 260128 ITERATIONS SEARCH TIME: 00.00.09

70 SEA SSS FUL L1

70 ANSWERS

=> fil caplus

L3

COST IN U.S. DOLLARS

TOTAL SINCE FILE

ENTRY SESSION

FULL ESTIMATED COST

140.54 140.69

FILE 'CAPLUS' ENTERED AT 14:18:11 ON 15 JAN 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December

26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1907 - 15 Jan 2002 VOL 136 ISS 3 FILE LAST UPDATED: 14 Jan 2002 (20020114/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAplus now provides online access to patents and literature covered in CA from 1907 to the present. Bibliographic information and abstracts were added in 2001 for over 3.8 million records from 1907-1966.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.

Attention, the CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

=> s 13 full

L48 L3

=> d 14 1-8 ibib abs hitstr

ANSWER 1 OF 8 CAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2001:631913 CAPLUS

DOCUMENT NUMBER: 135:195556

Preparation of azolylphenyl oxamides as inosine TITLE:

monophosphate dehydrogenase (IMPDH) inhibitors

Broadhurst, Michael John; Hill, Christopher Huw; INVENTOR(S):

Hurst, David Nigel; Jones, Philip Stephen; Kay, Paul Brittain; Kilford, Ian Reginald; Mckinnell, Robert

Murray

F. Hoffmann-La Roche A.-G., Switz. PATENT ASSIGNEE(S):

SOURCE: Eur. Pat. Appl., 256 pp.

CODEN: EPEKDW

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND D	DATE	APPLICATION NO		DATE		
				_			
EP 1127883	A2 2	20010829	EP 2001-103521		20010216		
R: AT, BE,	CH, DE,	DK, ES, FR,	GB, GR, IT, LI,	LU,	NL, SE,	MC,	PT,
IE, SI,	LT, LV,	FI, PO					
NO 2001000900	A 2	20010827	NO 2001-900		20010222		
CN 1310179	A 2	00010829	CN 2001-104906		20010223		
JP 2001261663	A2 0	0010926	JP 2001-51064		20010226		
PRIORITY APPLN. INFO	. :		GB 2000-4392	Ą	20000224		
			GB 2000-15877	Ą	20000628		
			GB 2000-20322	A	20000817		

```
^{R^2}
^{P^1}
^{R^3}
^{O}
^{NR^4R^8}
^{R^5}
^{O}
^{I}
```

AB Title compds. (I; R1 = heterocyclyl; R2 = H, alkyl, alkoxy, halo, OH, cyano; R3 = H, alkyl, alkoxy, halo, cyano; R4 = H, alkyl, cycloalkyl, aryl, heterocyclyl; R5 = H, alkyl, alkoxy, halo, cyano; R6 = H, alkyl, alkoxy, halo, cyano; R7, R8 = H, alkyl; R4R8N = heterocyclyl), were prepd.

Thus, 1,1-dimethyl-3-(4-nitrophenoxy)propylamine (prepn. given) was coupled with N-[3-methoxy-4-(5-oxazolyl)phenyl]oxamic acid in the presence

of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and 1-hydroxy-7-azabenzotriazole to give N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-dimethyl-3-(4-nitrophenoxy)propyl]oxalamide. Tested I inhibited IMPDH with IC50 = 0.010-0.277 .mu.M. I can be used for treating immune mediated

conditions or diseases, viral diseases, bacterial diseases, parasitic diseases, inflammation, inflammatory diseases, hyperproliferative rascular

diseases, tumors, and cancer.

```
TΤ
     267405-69-6P 357179-57-8P 357179-58-9P
     357179-59-0P 357179-69-2P 357179-71-6P
     357179-74-9P 357179-88-5P 357180-70-2P
     357180-82-6P 357180-83-7P 357180-84-8P
     357180-85-9P 357180-86-0P 357180-95-1P
     357180-96-2P 357180-97-3P 357180-98-4P
     357180-99-5P 357181-00-1P 357181-01-2P
     357181-02-3P 357181-03-4P 357181-36-3P
     357181-37-4P 357181-38-5P 357181-40-9P
     357181-41-0P 357181-42-1P 357181-43-2P
     357181-44-3P 357181-45-4P 357181-46-5P
     357181-47-6P 357181-48-7P 357181-49-8P
     357181-50-1P 357181-51-2P 357181-52-3P
     357181-53-4P 357181-54-5P 357181-55-6P
     357181-72-7P 357181-73-8P 357181-76-1P
     357181-79-4P 357181-80-7P 357181-81-8P
     357181-84-1P 357182-74-2P 357182-78-6P
     357183-19-8P
```

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of azolylphenyl oxamides as inosine monophosphate dehydrogenase

(IMPDH) inhibitors)

RN 267405-69-6 CAPLUS

CN Alanine, N-[3-methoxy-4-(5-oxazolyl)phenyl]-2-oxoglycyl-2-methyl- (9CI) (CA INDEX NAME)

MeO ...

Me O

HO2C C NH C-C-NH


Me O

RN 357179-57-8 CAPLUS


CN Acetic acid,

[4-[2-[[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]amin o]-2-methylpropyl]phenoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 357179-58-9 CAPLUS

CN Acetic acid,

[2-[2-[[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]amin o]-2-methylpropyl]phenoxy]- (9CI) (CA INDEX NAME)

NH

C - - O

C===== 0

NH

 ${\rm Me}-{\rm C}-{\rm Me}$

CH₂

RN 357179-59-0 CAPLUS

CN Acetic acid,

[3-[2-[[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]amin o]-2-methylpropyl]phenoxy]- (9CI) (CA INDEX NAME)

0 . MeO

NH

C 0

C . O

ИН

Me - C Me

CH₂

PAGE 2-A

RN 357179-69-2 CAPLUS

RN 357179-69-2 CN Benzoic acid,

4-[2-[[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]amin o]-2-methylpropyl]- (9CI) (CA INDEX NAME)

0 - Сн2—СО2н

0 .

NH

C - 0

C 0

NH

Me = C - Me

CH2

PAGE 2-A



CO2H

RN 357179-71-6 CAPLUS CN Benzoic acid,

3-[2-[[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]amin o]-2-methylpropyl]- (9CI) (CA INDEX NAME)

MeO

NH

c o

C ... 0

ИН

Me C- Me

CH₂

PAGE 2-A

CO₂H

RN 357179-74-9 CAPLUS

CN 5-Benzofurancarboxylic acid, 2-[2-[[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]amino]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Me O O O O O NH O N Me

RN 357179-88-5 CAPLUS

CN Benzo[b]thiophene-5-carboxylic acid, 2-[2-[[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]amino]-2-methylpropyl]- (9CI) (CA INDEX NAME)

```
Me OO O ....O

S
CH2 C NH C C NH

Me
```

HO2C

RN 357180-70-2 CAPLUS

CN Benzoic azid,

4-[[[4-[2-[[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]amino]-2-methylpropyl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

u
CN Benzoic acid,
4-[3-[[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]amin
o]-3-methylbutoxy]- (9CI) (CA INDEX NAME)

⇒ d 14 2-8 ibib abs hitstr

L4 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2001:12455 CAPLUS

DOCUMENT NUMBER: 134:86041

TITLE: Preparation of carbamate prodrugs for inhibition of

inosine monophosphate dehydrogenase (IMPDH)

INVENTOR(S): Stamos, Dean P.; Bethiel, Randy S.

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 63 pp.


CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KI					IND DATE				APPLICATION NO.					DATE				
WO	2001000622 A			1	2001	0104		WO 2000-US17400				00	20000623					
	W:	ΑE,	AG,	AL,	AM,	AT,	ΑU,	AΞ,	BA,	BB,	BG,	BR,	BY,	BΖ,	CA,	CH,	CN,	
		CR,	CU,	CZ,	DE,	DK,	DM,	DΣ,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,	
		HU,	ID,	ΙL,	IN,	IS,	JP,	KE,	KG,	ΚP,	KR,	KΖ,	LC,	LK,	LR,	LS,	LT,	
		LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MΣ,	MΖ,	NO,	NΖ,	PL,	PT,	RO,	RU,	
		SD,	SE,	SG,	SI,	SK,	SL,	TJ,	ΤM,	TR,	TT,	ΤZ,	UA,	UG,	US,	UZ,	VN,	
		YU,	ZA,	ZW,	AM,	ΑZ,	BY,	KG,	KΖ,	MD,	RU,	ТJ,	MT					
	RW:	GH,	GM,	ΚE,	LS,	MW,	MΖ,	SD,	SL,	SZ,	TZ,	UG,	ZW,	AT,	BE,	CH,	CY,	
		DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	ΙT,	LU,	MC,	NL,	PT,	SE,	BF,	вJ,	
		CF,	CG,	CI,	CM,	GΑ,	GN,	GW,	ML,	MR,	NE,	SN,	TD,	ΤG				
PRIORITY APPLN. INFO.:									US 1	999-	1411	02	P	1999	0625			
OTHER SOURCE(S):				MARPAT 134:86041														
GI																		



AB Carbamate prodrugs I [W = (un)substituted monocyclic or bicyclic, (un)satd. or arom. ring system consisting of 5-6 members per ring (optionally heterocyclic); D = NR3CONR3, CONR3, NR3CO, NR3COCR4:CR4 where each R3 = H, (un)substituted alkyl, alkenyl or alkynyl; R4 = R3, (un)substituted alkyl, alkenyl or alkenyl attached via O, OCO, S, SO, SO2,

SCO, NR3, or NR3CO; A = W, alkyl, alkenyl, or alkynyl where A optionally comprises up to 2 substituents wherein: the first of said substituents is R5 or W, and the second substituent, if present, is R5; R5 = (un) substituted 1,2-methylenedioxy, 1,2-ethylenedioxy, alkyl, alkenyl or alkynyl or (CH2)nW1; W1 = halo, CN, NO2, CF3, OH, alkoxy, etc.; n = 0-2;

= NHR6; R6 = H, (un)substituted alkyl, alkenyl, alkynyl, aryl or alkylaryl

and any NR6, taken together with the nitrogen and a carbon adjacent to the $\,$

nitrogen, optionally forms a 5-7 membered ring, wherein said ring optionally contains up to 3 addnl. heteroatoms; Z = (un) substituted alkyl,

alkenyl, alkynyl, aryl-alkyl, -alkenyl or -alkynyl, wherein up to 3 carbon

atoms may be replaced with O, S, SO, SO2, or NR6, wherein up to 3 CH2 groups may be replaced with CO; R1 = (un)substituted alkyl; R2 = H, CF3, alkyl, alkyl-W, W, or R1 and R2 together form a ring as defined in W], that on metab. convert to active inhibitors (formula II) of the IMPDH enzyme in vivo, were prepd. Thus, III.cntdot.HCl was prepd. from methylaminobutyric acid in seven steps. I and pharmaceutical compns. thereof are particularly well suited for activation and subsequent inhibition of the IMPDH enzyme activity. The rate of absorption of I via oral uptake of the prodrugs was dependent on the nature of substituents Z and Y, as well as the pH, with AUC values ranging from <1 to 5 mg.cntdot.hr/mL. Consequently, I may be advantageously used as therapeutic agents for IMPDH-mediated processes, e.g., cell proliferation (antitumor agents), and viral replication (antiviral agents).

T 317345-76-9P

Υ

RL: BAC (Biological activity or effector, except adverse); BPR (Biological $% \left(1\right) =\left(1\right) +\left(1\right)$

process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL
(Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (prepn. and biol. activity of N,N'-diphenylurea prodrugs of carbamate inhibitors of IMPDH)

RN 317345-76-9 CAPLUS

```
N-[[3-[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]carbonyl]amino
    ]phenyl]methyl]-N-[[[(3S)-tetrahydro-3-furanyl]oxy]carbonyl]-,
    monohydrochloride (9CI) (CA INDEX NAME)
Absolute stereochemistry.
                                            NH2
  0
                                0
                                               CO2H
                 ИН
   MeO
                                         0
                                             S
                    Н
                                      0
                      HCl
REFERENCE COUNT:
                        5
                        (1) Beylin, V; JOURNAL OF HETEROCYCLIC CHEMISTRY
REFERENCE(S):
1988,
                            V25(1), P97 CAPLUS
                        (2) Kahns, A; 1991, 6, P483 CAPLUS
                        (3) Kahns, A; INT J PHARM 1991, V71(1-2), P31 CAPLUS
                        (4) Sharma, S; JOURNAL OF MEDICINAL CHEMISTRY 1989,
                            V32(2), P357 CAPLUS
                        (5) Vertex Pharmaceuticals Incorporated; WO 9740028 A
                            1997 CAPLUS
    ANSWER 3 OF 8 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:688087 CAPLUS
DOCUMENT NUMBER:
                       133:261545
TITLE:
                       Inosine-5'-monophosphate dehydrogenase (IMPDH)
                        inhibitors, their preparation, and their therapeutic
                        use
                        Stamos, Dean; Trudeau, Martin; Bethiel, Scott; Badia,
INVENTOR(S):
                        Michael; Saunders, Jeffrey
                        Vertex Pharmaceuticals Incorporated, USA
PATENT ASSIGNEE(S):
SOURCE:
                        PCT Int. Appl., 89 pp.
                        CODEN: PIXXD2
DOCUMENT TYPE:
                        Patent
LANGUAGE:
                        English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
                 KIND DATE
                                         APPLICATION NO. DATE
    PATENT NO.
                          _____
    -----
                                         ______
    WO 2000056331 A1 20000928
                                       WO 2000-US7129 20000317
        W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
            CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID,
            IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,
            MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG,
            SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW,
```

L-Glutamine,

```
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
            DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
            CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                       US 1999-125507 P 19990319
PRIORITY APPLN. INFO.:
```

MARPAT 133:261545 OTHER SOURCE(S):

Compds. and pharmaceutical compns. are provided which inhibit IMPDH. The compds. and pharmaceutical compns. of the invention are particularly well suited for inhibiting IMPDH activity and consequently, may be used as therapeutic agents for IMPDH-mediated processes. The invention also relates to methods for inhibiting the activity of IMPDH using the compds. of the invention and related compds.

297728-82-6 297729-82-9 297729-83-0

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (inosine monophosphate dehydrogenase inhibitors, prepn., and therapeutic use)

RN

297728-82-6 CAPLUS Acetic acid, [[tetrahydro-4-[[[[[3-[[[3-methoxy-4-(5-CN oxazolyl)phenyl]amino]carbonyl]amino]phenyl]methyl]amino]carbonyl]oxy]-3furanyl]oxy] - (9CI) (CA INDEX NAME)

297729-82-9 CAPLUS

D-Aspartic acid, 1-[(2R)-2-[[[[[3-[[[3-methoxy-4-(5-

oxazolyl)phenyl]amino]carbonyl]amino]phenyl]methyl]amino]carbonyl]oxy]buty l] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

297729-83-0 CAPLUS RN

E-Glutamic acid, 1-[(2R)-2-[[[[[3-[[[3-methoxy-4-(5-CN

oxazolyl)phenyl]amino]carbonyl]amino]phenyl]methyl]amino]carbonyl]oxy]buty l] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

И

```
O HN O R Et O NH2
```

PAGE 1-B

__ CO2H

REFERENCE COUNT:

REFERENCE(S):

(1) Vertex Pharmaceuticals Incorporated; WO 9740028

A1

1997 CAPLUS

L4 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:

2000:314682 CAPLUS 132:334449

DOCUMENT NUMBER: TITLE:

Preparation of N-[4-(5-oxazolyl)phenyl] amides as

novel inhibitors of IMPDH enzyme

INVENTOR(S):

Gu, Henry H.; Dhar, T. G. Murali; Iwanowicz, Edwin

PATENT ASSIGNEE(S):

Bristol-Myers Squibb Company, USA PCT Int. Appl., 99 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. K			KI	ND	DATE			APPLICATION NO.					DATE			
) 2000026197			 A	 1	2000	0511		WO 1999-US24889				 89	19991022			
W:	AL,	AM,	AT,	AU,	AΞ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CU,	CZ,	DE,
	DK,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,
	ΚE,	KG,	ΚP,	KR,	KΣ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	MD,	MG,	MK,	MN,
	MW,	MX,	NO,	NΖ,	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,
	TR,	TT,	UA,	UG,	UΣ,	VN,	YU,	ZA,	ZW,	AM,	AZ,	BY,	KG,	KΣ,	MD,	RU,
	ТJ,	TM														
RW:	GH,	GM,	KE,	LS,	MW,	SD,	SL,	SZ,	ΤZ,	UG,	ZW,	ΑT,	BE,	CH,	CY,	DE,
	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	BF,	ВJ,	CF,
	CG,	CI,	CM,	GΑ,	GN,	GW,	ML,	MR,	NE,	SN,	TD,	ΤG				
11270	054		A	1	2001	0829		E	P 19	99-9	6014	5	19991022			
R:	AT,	BE,	CH,	DE,	DK,	ES,	FP,	GB,	GR,	ΙΤ,	LI,	LU,	NL,	SE,	MC,	PT,
	ΙE,	SI,	LT,	LV,	FΙ,	RO										
APPI	LN.	INFO	. :				1	JS 19	998-	1061	80	P	1998	1029		
							7	WO 19	999-1	US24	889	W	1999	1022		
	2000 W: RW:	20000261 W: AL, DK, KE, MW, TR, TJ, RW: GH, CG, 1127054 R: AT, IE,	2000026197 W: AL, AM, DK, EE, KE, KG, MW, MX, TR, TT, TJ, TM RW: GH, GM, DK, ES, CG, CI, 1127054 R: AT, BE, IE, SI,	2000026197 A W: AL, AM, AT, DK, EE, ES, KE, KG, KP, MW, MX, NO, TR, TT, UA, TJ, TM RW: GH, GM, KE, DK, ES, FI, CG, CI, CM, 1127054 A R: AT, BE, CH,	2000026197 A1 W: AL, AM, AT, AU,	W: AL, AM, AT, AU, AZ, DK, EE, ES, FI, GB, KE, KG, KP, KR, KZ, MW, MX, NO, NZ, PL, TR, TT, UA, UG, UZ, TJ, TM RW: GH, GM, KE, LS, MW, DK, ES, FI, FR, GB, CG, CI, CM, GA, GN, 1127054 R: AT, BE, CH, DE, DK, IE, SI, LT, LV, FI,	2000026197 A1 20000511 W: AL, AM, AT, AU, AZ, BA,	2000026197 A1 20000511 W: AL, AM, AT, AU, AZ, BA, BB, DK, EE, ES, FI, GB, GD, GE, KE, KG, KP, KR, KZ, LC, LK, MW, MX, NO, NZ, PL, PT, RO, TR, TT, UA, UG, UZ, VN, YU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, DK, ES, FI, FR, GB, GR, IE, CG, CI, CM, GA, GN, GW, ML, 127054 A1 20010829 R: AT, BE, CH, DE, DK, ES, FR, IE, SI, LT, LV, FI, RO APPLN. INFO.:	W: AL, AM, AT, AU, AZ, BA, BB, BG, DK, EE, ES, FI, GB, GD, GE, GH, KE, KG, KP, KR, KZ, LC, LK, LR, MW, MX, NO, NZ, PL, PT, RO, RU, TR, TT, UA, UG, UZ, VN, YU, ZA, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, DK, ES, FI, FR, GB, GR, IE, IT, CG, CI, CM, GA, GN, GW, ML, MR, 127054 R: AT, BE, CH, DE, DK, ES, FR, GB, IE, SI, LT, LV, FI, RO APPLN. INFO.: US 19	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, DK, EE, ES, FI, GB, GD, GE, GH, GM, KE, KG, KP, KR, KZ, LC, LK, LR, LS, MW, MX, NO, NZ, PL, PT, RO, RU, SD, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, DK, ES, FI, FR, GB, GR, IE, IT, LU, CG, CI, CM, GA, GN, GW, ML, MR, NE, 127054 R: AT, BE, CH, DE, DK, ES, FP, GB, GR, IE, SI, LT, LV, FI, RO APPLN. INFO.: US 1998-	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, I27054 R: AT, BE, CH, DE, DK, ES, FP, GB, GR, IT, IE, SI, LT, LV, FI, RO APPLN. INFO.: W0 1999-US W1 1999-US W	2000026197 Al 20000511 W0 1999-US248 W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, 1127054 Al 20010829 EP 1999-96014 R: AT, BE, CH, DE, DK, ES, FP, GB, GR, IT, LI, IE, SI, LT, LV, FI, RO APPLN. INFO.: US 1998-106180	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG 1127054 R: AT, BE, CH, DE, DK, ES, FP, GB, GR, IT, LI, LU, IE, SI, LT, LV, FI, RO APPLN. INFO.: WO 1999-US24889 WO 1999-US 1999-US 1999 WO	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG 1127054 Al 20010829 EP 1999-960145 1999. R: AT, BE, CH, DE, DK, ES, FP, GB, GR, IT, LI, LU, NL, IE, SI, LT, LV, FI, RO APPLN. INFO:: US 1998-106180 P 1998.	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG 1127054 A1 20010829 EP 1999-960145 19991022 R: AT, BE, CH, DE, DK, ES, FP, GB, GR, IT, LI, LU, NL, SE, IE, SI, LT, LV, FI, RO	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG 1127054 R: AT, BE, CH, DE, DK, ES, FP, GB, GR, IT, LI, LU, NL, SE, MC, IE, SI, LT, LV, FI, RO APPLN. INFO: US 1998-106180 P 19981029

OTHER SOURCE(S): MARPAT 132:334449

GΙ

н о

MeO N

N

Н

И

ΙI

AB The title compds. ZJKLX [I; Z = (un) substituted monocyclic or bicyclic ring system contg. up to 4 heteroatoms selected from N, O, and S; J = NR7,

CO; K = NR7, CO, CHR9; L = a single bond, CO, CR10R11, etc.; X = alkyl, alkenyl, cycloalkylalkyl, etc.; R7 = H, alkyl, alkenyl, etc.; R9 = H, alkyl, alkenyl, etc.; R10, R11 = H, F, Cl, etc.], useful in treating or preventing IMPDH assocd. disorders, such as transplant rejection and autoimmune disease, were prepd. E.g., a multi-step synthesis of gycinamide II was given. Compds. I are effective at 0.1-500 mg/kg/day.

IT 267405-69-6P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-[4-(5-oxazolyl)phenyl] amides as novel inhibitors of

IMPDH

enzyme)

RN 267405-69-6 CAPLUS

CN Alanine, N-[3-methoxy-4-(5-oxazolyl)phenyl]-2-oxoglycyl-2-methyl- (9CI) (CA INDEX NAME)

IT 267406-37-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. of N-[4-(5-oxazolyl)phenyl] amides as novel inhibitors of

IMPDH

enzyme)

RN 267406-37-1 CAPLUS

CN Propanoic acid, 3-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)

0

MeC

HO2C CH2 C-NH

0

REFERENCE COUNT:

PEFERENCE(S):

3

(1) Diana; US 4861791 A 1989 CAPLUS (2) Djuric; US 5073562 A 1991 CAPLUS

(3) Goldstein; US 5334604 A 1994 CAPLUS

L4 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:

2000:314540 CAPLUS

DOCUMENT NUMBER:

132:334477

TITLE:

Preparation of compounds derived from an amine

nucleus

as inhibitors of IMPDH enzyme

INVENTOR(S):

Liu, Chunjian; Dhar, T. G. Murali; Gu, Henry H.; Iwanowicz, Edwin J.; Leftheris, Katerina; Pitts,

William John

PATENT ASSIGNEE(S):

Bristol-Myers Squibb Company, USA

SOURCE:

PCT Int. Appl., 191 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent English

LANGUAGE:

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PA	PATENT NO.					DATE			APPLICATION NO.						DATE				
WC	2000	0257	80	A1 20000511				WO 1999-US24825 199910							1022				
	W:	AL,	AM,	AT,	ΑU,	AZ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CU,	CZ,	DE,		
		DK,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,	HU,	ID,	ΙL,	III,	IS,	JP,		
		ΚE,	KG,	ΚP,	KR,	ΚZ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	MD,	MG,	MK,	MN,		
		MW,	MX,	NO,	NZ,	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ТJ,	TM,		
		TR,	TT,	UA,	UG,	UZ,	VN,	YU,	ZA,	ZW,	AM,	ΑZ,	BY,	KG,	KΖ,	MD,	RU,		
		ТJ,	TM																
	RW:	GH,	GM,	KE,	LS,	MW,	SD,	SL,	SZ,	TZ,	UG,	ΖW,	AT,	BE,	CH,	CY,	DE,		
														SE,					
						GN,													
EF	EP 1126843				1	2001	0829		EP 1999-955142										
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	ΙT,	LI,	LU,	ΝL,	SE,	MC,	PT,		
		IE,	SI,	LT,	LV,	FI,	RO												
PRIORIT	Y APP	LN.	INFO	. :					US 1	998-	1061	86	P	1998	1029				
								,	wo 1	999-1	US24	825	W	1999	1022				

OTHER SOURCE(S): MARPAT 132:334477

AB The title compds. XN(R)BD [I; X = (un)substituted monocyclic or bicyclic ring system optionally contg. up to 4 heteroatoms selected from N, O, and S; R = H, alkyl; B = (un)substituted monocyclic or bicyclic ring system optionally contg. up to 4 heteroatoms selected from N, O, and S; D = (un)substituted monocyclic or bicyclic ring system optionally contg. up

4 heteroatoms selected from N, O, and S], useful in treating or preventing

IMPDH (inosine-5'-monophosphate dehydrogenase) mediated diseases, such as transplant rejection and autoimmune diseases, were prepd. E.g., a multi-step synthesis of triazole II was given. Compds. I are effective

at

0.1-500 mg/kg/day.

IT 267648-02-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. of compds. derived from an amine nucleus as inhibitors of IMPDH

enzyme)

RN 267648-02-2 CAPLUS

CN Benzoic acid, 2-[2-[[(1,1-dimethylethoxy)carbonyl][3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]- (9CI) (CA INDEX NAME)

0

C- OBu-t

R

PEFERENCE COUNT:

REFERENCE(S): (1) Knox; US 5247083 A 1993 CAPLUS

L4 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2000:268526 CAPLUS

DOCUMENT NUMBER: 132:288797

TITLE: Inosine 5'-monophosphate dehydrogenase (IMPDH)

inhibitor preparation for therapeutic use

INVENTOR(S): Armistead, David M.; Badia, Michael C.; Bemis, Guy

W.;
Bethiel, Randy S.; Frank, Catharine A.; Novak, Perry

M.; Ronkin, Steven M.; Saunders, Jeffrey O. PATENT ASSIGNEE(S): Vertex Pharmaceuticals, Incorporated, USA

S): Vertex Pharmaceuticals, Incorporated, USA U.S., 22 pp., Cont.-in-part of U.S. 5,807,876.

CODEN: USXXAM

DOCUMENT TYPE:

SOURCE:

LANGUAGE:

Patent English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

	PATENT NO.								APPLICATION NO.									
		5054													1997	0402		
	US	5307	876		A		1998	0915		U	s 19	96-6	3636	1	1996	0423		
	WO	9740	028		A	1	1997	1030		W	0 19	97-U	S662	3	1997	0421		
		W:	AL,	AM,	AT,	ΑU,	ΑZ,	ВA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CU,	CZ,	DE,
			DK,	EE,	ES,	FI,	GB,	GE,	GH,	HU,	IL,	IS,	JP,	ΚE,	KG,	ΚP,	KR,	KΖ,
			LC,	LK,	LR,	LS,	LT,	LU,	LV,	MD,	MG,	MK,	MN,	MW,	MΣ,	NO,	NZ,	PL,
															UA,			
							KG,											
		RW:	GH,	KE,	LS,	MW,	SD,	SZ,	UG,	AT,	BE,	CH,	DE,	DK,	ES,	FΙ,	FR,	GB,
			GR,	IE,	IT,	LU,	MC,	NL,	PT,	SE,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,
			ML,	MR,	NE,	SN,	TD,	TG										
	AU	9726	785		A	1	1997	1112		А	U 19	97-2	6785		1997	0421		
	ΑU	7237	30		В	2	2000	0907										
	ΕP	9027	82		A	1	1999	0324		E	P 19	97-9	1875	9	1997	0421		
		R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,
			ΙE,	SI,	LT,	LV,	FI,	P.O										
	CN	1219	929		A		1999	0616		C	N 19	97-1	9485	6	1997	0421		
		9708													1997	0421		
	JΡ	2001	5091	32	\mathbf{T}^{2}	2	2001	0710		J	P 19	97-5	3823	4	1997	0421		
	NO	9804	917		A		1998	1223		N	0 19	98-4	917		1998	1022		
		2000									R 19	98-7	0845	4	1998	1022		
PRIOR	ITY	APP	LN.	INFO	. :				1	US 1	996-	6363	61	A2	1996	0423		
															1997			
									1	US 1	997-	8321	65	А	1997	0402		
									1	WO 1	997-	US 66	23	W	1997	0421		
	~ -	~-								^ _								

OTHER SOURCE(S): MARPAT 132:288797

AB The invention relates to a novel class of compds. which are IMPDH inhibitors. This invention also relates to pharmaceutical compns. comprising these compds. The compds. and pharmaceutical compns. of the invention are particularly well suited for inhibiting IMPDH activity and consequently may be used as therapeutic agents for IMPDH-mediated processes. The invention also relates to methods for inhibiting the activity of IMPDH using the compds. of the invention and related compds.

198820-33-6 198820-44-9 198820-62-1
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(inosine monophosphate dehydrogenase inhibitor prepn. for therapeutic use)

RN 198820-33-6 CAPLUS

ΙT

CN Benzenepropanoic acid, 3-[[[[4-(5-oxazolyl)phenyl]amino]carbonyl]amino](9CI) (CA INDEX NAME)

```
Ν
```

0

NΗ

 $C_{\cdot,\cdot} = 0$

ΝH

 $\mathrm{CH_2}-\mathrm{CH_2}-\mathrm{CO_2H}$

RΝ 198820-44-9 CAPLUS

CN Benzeneacetic acid, 3-[[[[4-(5-oxazolyl)phenyl]amino]carbonyl]amino]-(9CI) (CA INDEX NAME)

Ν

ИН

C ---- O

ИН

 $\mathtt{CH}_2 - \mathtt{CO}_2 \mathtt{H}$

198820-62-1 CAPLUS RN

CN Benzeneacetic acid,

3-[[[[3-chloro-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

0 .

Cl

ΝН

C -0

ИИ

 $CH_2 - CO_2H$

REFERENCE COUNT:

13

REFERENCE(S): (1) Anon; US 4048333 1977 CAPLUS

(2) Anon; WO 9401105 1994 CAPLUS

(3) Anon; WO 9412184 1994 CAPLUS (4) Anon; US 5380879 1995 CAPLUS

(5) Anon; US 5444072 1995 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 7 OF 8 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:

1997:717901 CAPLUS

DOCUMENT NUMBER:

128:3680

TITLE:

Preparation of arylreas and related compounds as inhibitors of inosine 5'-monophosphate dehydrogenase.

INVENTOR(S):

Armistead, David M.; Badia, Michael C.; Bemis, Guy

W.;

Bethiel, Randy S.; Frank, Catharine A.; Novak, Perry

M.; Ronkin, Steven M.; Saunders, Jeffrey O.

PATENT ASSIGNEE(S):

Vertex Pharmaceuticals Inc., USA

SOURCE:

PCT Int. Appl., 93 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:


English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PAT	CENT	NO.		KI	ND	DATE			A.	PPLI	CATI	ON NO	٥.	DATE			
WO	9740	028		A	1	1997	1030		W	0 19	97-U	s662	3	1997	0421		
	W:	AL,	AM,	AT,	AU,	AΖ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CIJ,	CZ,	DE,
		DK,	EE,	ES,	FI,	GB,	GE,	GH,	HU,	IL,	IS,	JP,	ΚE,	KG,	ΚP,	KR,	ΚZ,
		LC,	LK,	LR,	LS,	LT,	LU,	LV,	MD,	MG,	MK,	MN,	MW,	MΣ,	NO,	NΖ,	PL,
		PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	ТJ,	TM,	TR,	TT,	UA,	UG,	UZ,	VN,
		YU,	AM,	AZ,	BY,	KG,	KΣ,	ΜĽ,	RU,	ТJ,	TM						
	RW:	GH,	ΚE,	LS,	MW,	SD,	SZ,	UG,	AT,	BE,	CH,	DE,	DK,	ES,	FI,	FR,	GB,
		GR,	ΙE,	ΙΤ,	LU,	MC,	NΙ,	PT,	SE,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,
		ML,	MR,	NE,	SN,	TU,	TG										
US	5807	876		A		1998	0915		U:	5 19	96-6	3636	1	1996	0423		
US	6054	472		A		2000	0425		US	5 19	97-8	3216	5	1997	0402		
ΑU	9726	785		A.	1	1997	1112		Α	J 19	97-2	6785		1997	0421		
ΑU	7237	30		B	2	2000	0907										
ΕP	9027	82		A.	1	1999	0324		E	9 199	97-91	1875	9	1997	0421		
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FP,	GB,	GR,	ΙΤ,	LI,	LU,	NL,	SE,	MC,	PT,
		ΙE,	SI,	LT,	LV,	FΙ,	RO										
BR	9708	735		А		1999	0803		BI	3 199	97-8	735		1997	0421		

```
JP 2001509132
                    T2
                            20010710
                                          JP 1997-538234 19970421
                      A 19981223
                                                            19981022
                                          NO 1998-4917
    NO 9804917
                                        US 1996-636361 A 19960423
PRIORITY APPLN. INFO.:
                                        US 1997-801780 A 19970214
US 1997-832165 A 19970402
                                                       A
W
                                                           19970421
                                        WO 1997-US6623
                       MARPAT 128:3680
OTHER SOURCE(S):
    ANHINHB [A = (substituted) alkyl, alkenyl, alkynyl; B = (unsatd.)
     (substituted) mono- or bicyclic ring contg. .ltoreq.4 heteroatoms; D =
CO,
     CS, SO2], were prepd. Thus, 4-(5-oxazolyl)aniline and PhCH2NCO were
     stirred overnight in CH2Cl2 to give N-benzyl-N'-[4-(5-
     oxazolyl)phenyl]urea. Several title compds. inhibited IMPDH with Ki =
     0.01-50 nM.
     198820-33-6 198820-44-9 198820-62-1
IΤ
     RL: BAC (Biological activity or effector, except adverse); THU
     (Therapeutic use); BIOL (Biological study); USES (Uses)
        (prepn. of arylreas and related compds. as inhibitors of IMP
        dehydrogenase)
     198820-33-6 CAPLUS
RN
     Benzenepropanoic acid, 3-[[[[4-(5-oxazolyl)phenyl]amino]carbonyl]amino]-
CN
     (9CI) (CA INDEX NAME)
И
```



RN 198820-44-9 CAPLUS
CN Benzeneacetic acid, 3-[[[[4-(5-oxazolyl)phenyl]amino]carbonyl]amino](9CI) (CA INDEX NAME)

NH

C==:00

ИИ

 CH_2 - CO_2H

RN 198820-62-1 CAPLUS CN Benzeneacetic acid,

3-[[[[3-chloro-4-(5-oxazolyl)phenyl]amino]carbonyl]ami no] - (9CI) (CA INDEX NAME)

NH $C_{i} = 0$

NH

 $\mathrm{CH_2}-\mathrm{CO_2H}$

ANSWER 8 OF 8 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1988:507387 CAPLUS

DOCUMENT NUMBER: TITLE:

SOURCE:

109:107387 Homogeneous fluoroassay methods employing fluorescent background rejection and water-soluble rare earth

metal chelate fluorophores

INVENTOR(S):

Wieder, Irwin; Hale, Ron L.

PATENT ASSIGNEE(S):

Baxter Travenol Laboratories, Inc., USA

PCT Int. Appl., 69 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent English

LANGUAGE:

FAMILY ACC. NUM. COUNT: 2 PATENT INFORMATION:

PATENT NO. KIND DATE

APPLICATION NO. DATE

```
WO 3707955
                     Al 19871230
                                          WO 1987-US1407 19870615
         W: DK, FI, JP, NO
         RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE
    EP 272320 A1 19880629
                                          EP 1987-905011
                                                            19870615
                           19940323
     EP 272320
                      В1
        R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE
    JP 01500458 T2 19890216 JP 1987-504676
                                                            19870615
    AT 103393
CA 1309016
                                           AT 1987-905011
                       Ε
                            19940415
                                                             19870615
                     Al
                                                             19870616
                            19921020
                                           CA 1987-539778
                           19880216
                                           DK 1988-798
     DK 8800798
                                                             19880216
                       A
    DK 172464 B1 19980831
FI 8800719 A 19880216
FI 93997 B 19950315
FI 93997 C 19950626
NO 8800684 A 19880412
US 5830769 A 19981103
US 6242268 B1 20010605
                      B1 19980831
                                           FI 1988-719
                                                             19880216
                                          NO 1988-684
                                                             19880216
                                           US 1996-732871 19961015
                                         US 1998-184330 19981102
PRIORITY APPLN. INFO.:
                                         US 1986-875287 A 19860617
                                         US 1985-712774 A2 19850318
                                         US 1985-712779 A2 19850318
                                         EP 1987-905011 A 19870615
                                         WO 1987-US1407 W 19870615
                                         US 1993-35516 B1 19930322
                                         US 1994-338285 B1 19941110
                                         US 1996-732871 A1 19961015
```

 ${\tt AB}-{\tt Homogeneous}$ assays for detg. the extent of a specific binding reaction can

be carried out on very dil. solns. using fluorescence measurements if a fluorescence measurement scheme is employed that is capable of rejecting short-lived background fluorescence. The fluorescent group must be a water-sol. rare earth metal chelate which is stable in extremely dil. aq. solns., i.e. it must have .gtoreq.1 ligand with a binding const. of .gtoreq.1013 M-1. It must also have a fluorescent emission of long duration compared to the longest decay lifetime of ambient substances and must have a half-life of 0.01-50 ms. An energy transfer fluorescence enhancement assay for theophylline was carried out by allowing theophylline in a sample to compete for anti-theophylline antibody with a tracer, 2,6-bis[N,N-di(carboxymethyl)aminomethyl]-4-[4-(theophylline-8-butyramido)phenyl]pyridine Tb chelate (prepn. given). Theophylline could be detd. over the concn. range 5.4-540 ng/10 .mu.L, with an increase in the obsd. fluorescence of .ltoreq.400%.

IT 116241-45-3D, antibody conjugates

RL: ANST (Analytical study)

(as fluorescence enhancer for fluorescence immunoassay)

RN 116241-45-3 CAPLUS

CN Octanoic acid, 8-oxo-8-[[3-oxo-3-[[4-(2-phenyl-5-oxazolyl)phenyl]amino]propyl]amino]- (9CI) (CA INDEX NAME)

```
Ph N O N O O NH - C - CH<sub>2</sub> - CH<sub>2</sub> - NH - C - (CH<sub>2</sub>) 6 - CO<sub>2</sub>H O
```

Executing the logoff script...

=> LOG Y

= •

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	36.07	176.76
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.96	-4.96

STN INTERNATIONAL LOGOFF AT 14:19:11 ON 15 JAN 2002

09779116 Page 1

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1613SXW

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
* * * * * * * * * *
                          Welcome to STN International
                     Web Page URLs for STN Seminar Schedule - N. America
NEWS
                     The CA Lexicon available in the CAPLUS and CA files
NEWS 2 Dec 17
NEWS 3 Feb 06 Engineering Information Encompass files have new names
NEWS 4 Feb 16 TOXLINE no longer being updated
NEWS 5 Apr 23 Search Derwent WPINDEX by chemical structure
NEWS 6 Apr 23 PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
NEWS 7 May 07 DGENE Reload
NEWS 9 Jun 20 Published patent applications (A1) are now in USPATFULL
NEWS 9 JUL 13 New SDI alert frequency now available in Derwent's
                      DWPI and DPCI
NEWS 10 Aug 23
                     In-process records and more frequent updates now in
                     MEDLINE
                     PAGE IMAGES FOR 1947-1966 RECORDS IN CAPLUS AND CA
NEWS 11 Aug 23
NEWS 12 Aug 23
                     Adis Newsletters (ADISNEWS) now available on STN
NEWS 13 Sep 17
                     IMSworld Pharmaceutical Company Directory name change
                      to PHARMASEARCH
NEWS 14 Oct 09 Korean abstracts now included in Derwent World Patents
                      Index
NEWS 15 Oct 09 Number of Derwent World Patents Index updates increased
NEWS 16 Oct 15 Calculated properties now in the REGISTRY/ZREGISTRY File
NEWS 17 Oct 22 Over 1 million reactions added to CASREACT
NEWS 17 Oct 22 Over 1 million reactions added to CASREACT
NEWS 18 Oct 22 DGENE GETSIM has been improved
NEWS 19 Oct 29 AAASD no longer available
NEWS 20 Nov 19 New Search Capabilities USPATFULL and USPAT2
NEWS 21 Nov 19 TOXCENTER(SM) - new toxicology file now available on STN
NEWS 22 Nov 29 COPPERLIT now available on STN
NEWS 23 Nov 29 DWPI revisions to NTIS and US Provisional Numbers
NEWS 24 Nov 30 Files VETU and VETB to have open access
NEWS 25 Dec 10 DGENE BLAST Homology Search
NEWS 26 Dec 17 WELDASEARCH now available on STN
NEWS 28 Dec 17 STANDARDS now available on STN
NEWS 28 Dec 17 STANDARDS now available on STN
NEWS 29 Dec 17 New fields for DPCI
NEWS 30 Dec 19 CAS Roles modified
NEWS 31 Dec 19 1907-1946 data and page images added to CA and CAplus
NEWS EMPRESS August 15 CURRENT WINDOWS VERSION IS V6.0c,
                  CURRENT MACINTOSH VERSION IS V6.0 (ENG) AND V6.0J (JP),
                  AND CURRENT DISCOVER FILE IS DATED 07 AUGUST 2001
                 STN Operating Hours Plus Help Desk Availability
NEWS HOURS
NEWS INTER
                 General Internet Information
NEWS LOGIN
                 Welcome Banner and News Items
                 Direct Dial and Telecommunication Network Access to STN
NEWS PHONE
NEWS WWW
                 CAS World Wide Web Site (general information)
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 10:28:12 ON 15 JAN 2002

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.15 0.15

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 10:28:17 ON 15 JAN 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 14 JAN 2002 HIGHEST RN 383122-99-4 DICTIONARY FILE UPDATES: 14 JAN 2002 HIGHEST RN 383122-99-4

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details: http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> Uploading 09779116.str

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS L1 STR 0

N

Ν

0

0

Structure attributes must be viewed using STN Express query preparation.

 \Rightarrow s 11 sss sam

SAMPLE SEARCH INITIATED 10:28:58 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 4271 TO ITERATE

1000 ITERATIONS 23.4% PROCESSED INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED) SEARCH TIME: 00.00.01

1 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS:

81504 TO 89336

PROJECTED ANSWERS:

1 TO 208

1 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 10:29:05 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED - 87001 TO ITERATE

100.03 PROCESSED 87001 ITERATIONS SEARCH TIME: 00.00.03

65 ANSWERS

65 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION

FULL ESTIMATED COST

140.69 140.54

FILE 'CAPLUS' ENTERED AT 10:29:14 ON 15 JAN 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1907 - 15 Jan 2002 VOL 136 ISS 3 FILE LAST UPDATED: 14 Jan 2002 (20020114/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAplus now provides online access to patents and literature covered in CA from 1907 to the present. Bibliographic information and abstracts were added in 2001 for over 3.8 million records from 1907-1966.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELF ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.

Attention, the CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

=> s 13 full

L4 6 L3

=> d 14 1-6 ibib abs hitstr

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2001:631913 CAPLUS

DOCUMENT NUMBER: 135:195556

TITLE: Preparation of azolylphenyl oxamides as inosine

monophosphate dehydrogenase (IMPDH) inhibitors

INVENTOR(S): Broadhurst, Michael John; Hill, Christopher Huw;

Hurst, David Nigel; Jones, Philip Stephen; Kay, Paul Brittain; Kilford, Ian Reginald; Mckinnell, Robert

Murray

PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.

SOURCE: Eur. Pat. Appl., 256 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO	DATE				
EP 1127883	A2	20010829	EP 2001-103521	_	20010216			
R: AT, BE,	CH, DE	, DK, ES, F	R, GB, GR, IT, LI,	LU,	, NL, SE,	MC,	PT,	
IE, SI,	LT, LV	, FI, RO						
NO 2001000900	A	20010827	NO 2001-900		20010222			
CN 1310179	A	20010829	CN 2001-104906	5	20010223			
JP 2001261663	A2	20010926	JP 2001-51064		20010226			
PRIORITY APPLN. INFO	. :		GB 2000-4392	A	20000224			
			GB 2000-15877	Α	20000628			
			GB 2000-20322	Α	20000817			

```
R^2
           R^3
R^{1}
                   NR4R8
p6
           N<sub>R</sub>7
      R^5
                0
                          Ι
     Title compds. (I; R1 = heterocycly1; R2 = H, alkyl, alkoxy, halo, OH,
AΒ
     cyano; R3 = H, alkyl, alkoxy, halo, cyano; R4 = H, alkyl, cycloalkyl,
     aryl, heterocyclyl; R5 = H, alkyl, alkoxy, halo, cyano; R6 = H, alkyl,
     alkoxy, halo, cyano; R7, R8 = H, alkyl; R4R8N = heterocyclyl), were
prepd.
     Thus, 1,1-dimethyl-3-(4-nitrophenoxy)propylamine (prepn. given) was
     coupled with N-[3-methoxy-4-(5-oxazolyl)phenyl] oxamic acid in the
presence
     of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and 1-hydroxy-7-
     azabenzotriazole to give N-[3-methoxy-4-(5-oxazolyl)phenyl]-N'-[1,1-
     dimethyl-3-(4-nitrophenoxy)propyl]oxalamide. Tested I inhibited IMPDH
     with IC50 = 0.010-0.277 .mu.M. I can be used for treating immune
mediated
     conditions or diseases, viral diseases, bacterial diseases, parasitic
     diseases, inflammation, inflammatory diseases, hyperproliferative
vascular
     diseases, tumors, and cancer.
ΙΤ
     357181-06-7P 357181-92-1P 357182-28-6P
     357182-29-7P 357182-30-0P 357182-31-1P
     357182-32-2P 357182-33-3P 357182-34-4P
     357182-35-5P 357182-36-6P 357182-37-7P
     357182-38-8P 357182-39-9P 357182-40-2P
     357182-41-3P 357182-42-4P 357182-43-5P
     357182-44-6P 357182-45-7P 357182-46-8P
     357182-47-9P 357182-48-0P 357182-49-1P
     357182-50-4P 357182-51-5P 357182-52-6P
     357182-53-7P 357182-54-8P 357182-55-9P
     357182-56-0P 357182-57-1P 357182-58-2P
     357182-59-3P 357182-60-6P 357182-61-7P
     357182-62-8P 357182-90-2P 357183-04-1P
     357183-07-4P 357184-40-8P 357184-66-8P
     357184-76-0P 357184-78-2P
     RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic
     preparation); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); USES (Uses)
        (prepn. of azolylphenyl oxamides as inosine monophosphate
dehydrogenase
        (IMPDH) inhibitors)
     357181-06-7 CAPLUS
RN
     Ethanediamide, N-[3-[4-(4-acetyl-1-piperazinyl)phenoxy]-1,1-
CN
```

dimethylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX

MARPAT 135:195556

OTHER SOURCE(S):

NAME)

O --MeO .

NH

C - 0

C 0


ΝН

Me-- C-- Me

CH₂

CH₂

PAGE 2-A



RN 357181-92-1 CAPLUS

CN Ethanediamide, N-[2-(4-benzoyl-1-piperazinyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)

0 .

MeO

ИН

C - --- O

 $C \cdot \cdots \ O$

ИН

Me-C-Me

CH2

PAGE 2-A

N. . 11

Ph-C

357182-28-6 CAPLUS Ethanediamide, N-[2-[4-(2,2-dimethyl-1-oxopropyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX

NAME)

N

O MeO

ΝН

C == O


C == : O

ИН

Me - C-Me

CH₂

PAGE 2-A



RN 357182-29-7 CAPLUS

CN Ethanediamide, N-[2-[4-(2-furanylcarbonyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)

RN 357182-30-0 CAPLUS

CN Ethanediamide, N-[1,1-dimethyl-2-[4-(2-thienylcarbonyl)-1-piperazinyl]ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)

OMe 0 0 0 0 Me C-Ν NH C C NH C CH2 N Me 357182-31-1 CAPLUS BNEthanediamide, N-[1,1-dimethyl-2-[4-(3-thienylcarbonyl)-1-CIIpiperazinyl]ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME) ОМе 0 0 Me N - C- - S The second of the contract of Me RN 357182-32-2 CAPLUS Ethanediamide, N-[2-[4-(cyclopentylacetyl)-1-piperazinyl]-1,1-CN dimethylethyl]-N'-(3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME) C- CH2---- NH- С · С-- NH-- С-- СН2-- N Me

RN 357182-33-3 CAPLUS
CN Ethanediamide, N-[2-[4-(cyclohexylcarbonyl)-1-piperazinyl]-1,1dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)

0 MeO

ΝН

C - O

NH

 ${\rm Me^{--}}$ ${\rm C^{--}}$ ${\rm Me}$

CH2

PAGE 2-A

N

357182-34-4 CAPLUS RN

CN Ethanediamide, N-[1,1-dimethyl-2-[4-(2-methylbenzoyl)-1-piperazinyl]ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)

ΝН

NH

$${\rm Me^-\,C^-\,Me}$$

CH₂

RN 357182-35-5 CAPLUS

CN Ethanediamide,

MeO

NH

C ", - - O

C: __ O

ΝН

 $\begin{array}{c} \text{Me-} C-\text{Me} \\ \vdots \\ \text{CH}_2 \end{array}$


PAGE 2-A

RN 357182-36-6 CAPLUS

CN Ethanediamide, N-[2-[4-(cycloheptylcarbonyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)

N O MeO NH C O NH Me C Me CH2

PAGE 2-A



RN 357182-37-7 CAPLUS

CN Ethanediamide, N-[1,1-dimethyl-2-[4-(1H-pyrazol-4-ylcarbonyl)-1-piperazinyl]ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)

OMe

O O O Me

N— C— NH

N— NH

Me

RN 357182-38-8 CAPLUS

CN Ethanediamide, N-[2-[4-(cyclopentylcarbonyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)

0

00 Me N 3 --

N - NH C - C NH C CH2 - N

Me

RN 357182-39-9 CAPLUS

CN Ethanediamide,

N-[1,1-dimethyl-2-[4-[(1-methyl-1H-pyrrol-2-yl)carbonyl]-1piperazinyl]ethyl]-N'-{3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)

OME O ME N--C-N--N--C-CH₂--N

Ме

RN 357182-40-2 CAPLUS

CN Ethanediamide, N-[1,1-dimethyl-2-[4-(1,2,3-thiadiazol-4-ylcarbonyl)-1-piperazinyl]ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)

OMe

O O Me

N--- NH- C--C NH- C--CH2-- N

Me

RN 357182-41-3 CAPLUS

CN Ethanediamide,

0 - . MeO

ИИ

C = 0

 $C_{\, i,j} = O$

ИII

Me - C - Me

CH₂

PAGE 2-A

357182-42-4 CAPLUS

CN Ethanediamide,

N-[2-[4-(4-fluorobenzoyl)-1-piperazinyl]-1,1-dimethylethyl]N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)

MeO .

NH

C == == 0

c = o

ΝН

Me C-Me

CH2

PAGE 2-A

N.

N

c== 0

F

RN 357182-43-5 CAPLUS

CN Ethanediamide, N-[2-[4-(cyclopropylcarbonyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)

O MeO

ИН

C---- 0

C - - O

NH

Me C-Me

CH2

PAGE 2-A

 N_{tot}

N

 $\mathbf{c}\mathbf{=}\mathbf{o}$

.

RN 357182-44-6 ÇAPLUS

CN Ethanediamide, N-[2-[4-(cyclohexylacetyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX

NAME)

0 -Me0 -

. .

NH

C- 0


C C

NH

Me - C Me

CH2

PAGE 2-A



RN 357182-45-7 CAPLUS

CN Ethanediamide, N-[2-[4-(3,3-dimethyl-1-oxobutyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)

N

0 MeO

NH

 C^{-1} 0

C-0

NH

 ${\rm Me}-{\rm C}-{\rm Me}$

CH₂

PAGE 2-A

, N. N Me_3C-CH_2-C 0

RN 357182-46-8 CAPLUS

CN Ethanediamide, N-[2-[4-(3-hydroxy-2,2-dimethyl-1-oxopropyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)

CH2

RN 357182-47-9 CAPLUS

CN Ethanediamide, N-[1,1-dimethyl-2-[4-[(3-methyl-2-furanyl)carbonyl]-1-piperazinyl]ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)

OMe

O O O Me

N - C - NH - C - CH2 - N

Me

Me

Me

RN 357182-48-0 CAPLUS

CN Ethanediamide, N-[1,1-dimethyl-2-[4-[(2-methyl-3-furanyl)carbonyl]-1-piperazinyl]ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)

Ме

RN 357182-49-1 CAPLUS

CN Ethanediamide,

N-[1,1-dimethyl-2-[4-[(5-methyl-1H-pyrazol-3-yl)carbonyl]-1piperazinyl]ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)

RN 357182-50-4 CAPLUS

CN Ethanediamide, N-[1,1-dimethyl-2-[4-[(5-methyl-4-isoxazolyl)carbonyl]-1-piperazinyl]ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)

RN 357182-51-5 CAPLUS

CN Ethanediamide, N-[1,1-dimethyl-2-[4-[(5-methyl-3-isoxazolyl)carbonyl]-1-piperazinyl]ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)

OME

O N Me

N C CH2 N Me

Me

Me

Me

Me

RN 357182-52-6 CAPLUS

CN Ethanediamide,

N-[2-[4-(4-aminobenzoyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME) N

O MeO

NH

C - - - O

C---- 0

NH

Me · C-Me

CH₂


PAGE 2-A

RN 357182-53-7 CAPLUS

CN Ethanediamide, N-[2-[4-(2-hydroxybenzoyl)-1-piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)

N O -- MeO NH C O NH Me C Me

PAGE 2-A



CH₂

RN 357182-54-8 CAPLUS
CN Ethanediamide, N-[2-[4-(4-hydroxybenzoyl)-1-piperazinyl]-1,1dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)

PAGE 2-A

OH C C C

RN 357182-55-9 CAPLUS
CN Ethanediamide, N-[2-[4-[(1,3-dimethyl-1H-pyrazol-5-yl)carbonyl]-1piperazinyl]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl](9CI)
(CA INDEX NAME)

u RN 357182-57-1 CAPLUS => d 14 2-6 ibib abs hitstr

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2001:12455 CAPLUS

DOCUMENT NUMBER: 134:86041

TITLE: Preparation of carbamate prodrugs for inhibition of

inosine monophosphate dehydrogenase (IMPDH)

INVENTOR(S): Stamos, Dean P.; Bethiel, Randy S.

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 63 pp.

CODEN: PIXXD2


DOCUMENT TYPE:

Patent English

LANGUAGE: I FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT	NO.	KIND	DATE			A	PPLI	CATI	N IIC	ο.	DATE					
WO 2001	WO 2001000622			A1 20010104				WO 2000-US1740				00 20000623				
W:	AE, AG	AL, AN	, AT,	AU,	AΞ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,		
	CR, CU,	CZ, DE	, DK,	DM,	DZ,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,		
	HU, ID,	IL, IN	, IS,	JP,	KE,	KG,	KP,	KR,	KΞ,	LC,	LK,	LR,	LS,	LT,		
	LU, LV	MA, MI	, MG,	MK,	MII,	MW,	Μ×.,	ΜZ,	110,	NΖ,	PL,	PT,	RO,	RU,		
	SD, SE	SG, SI	, SK,	SL,	ТJ,	TM,	TF.,	TT,	ΤZ,	UA,	UG,	US,	UZ,	VN,		
	YU, ZA	ZW, AN	I, AZ,	BY,	KG,	ΚZ,	MΓ,	RU,	TJ,	TM						
RW:	GH, GM	KE, LS	, MW,	ΜZ,	SD,	SL,	SZ,	TZ,	UG,	ZW,	ΑT,	BE,	CH,	CY,		
	DE, DK	ES, FI	, FR,	GB,	GR,	ΙE,	ΙΤ,	LU,	MC,	NL,	PT,	SE,	BF,	ВJ,		
	CF, CG	CI, CN	I, GA,	GN,	GW,	ML,	MP.,	NE,	SN,	TD,	ΤG					
PRIORITY API).:	US 1999-141102 P							Р	P 19990625						
OTHER SOURCE	MA	MARPAT 134:86041														



Carbamate prodrugs I [W = (un)substituted monocyclic or bicyclic, (un)satd. or arom. ring system consisting of 5-6 members per ring (optionally heterocyclic); D = NR3CONR3, CONR3, NR3CO, NR3COCR4:CR4 where each R3 = H, (un)substituted alkyl, alkenyl or alkynyl; R4 = R3, (un)substituted alkyl, alkenyl or alkenyl attached via O, OCO, S, SO,

SO2, SCO, NR3, or NR3CO; A = W, alkyl, alkenyl, or alkynyl where A optionally comprises up to 2 substituents wherein: the first of said substituents is R5 or W, and the second substituent, if present, is R5; R5 = (un)substituted 1,2-methylenedioxy, 1,2-ethylenedioxy, alkyl, alkenyl or alkynyl or (CH2)nW1; W1 = halo, CN, NO2, CF3, OH, alkoxy, etc.; n = 0-2;

Y = NHR6; R6 = H, (un) substituted alkyl, alkenyl, alkynyl, aryl or alkylaryl

and any NR6, taken together with the nitrogen and a carbon adjacent to the

nitrogen, optionally forms a 5-7 membered ring, wherein said ring optionally contains up to 3 addnl. heteroatoms; Z = (un) substituted alkyl,

alkenyl, alkynyl, aryl-alkyl, -alkenyl or -alkynyl, wherein up to 3 carbon

atoms may be replaced with O, S, SO, SO2, or NR6, wherein up to 3 CH2 groups may be replaced with CO; R1 = (un)substituted alkyl; R2 = H, CF3, alkyl, alkyl-W, W, or R1 and R2 together form a ring as defined in W], that on metab. convert to active inhibitors (formula II) of the IMPDH enzyme in vivo, were prepd. Thus, III.cntdot.HCl was prepd. from methylaminobutyric acid in seven steps. I and pharmaceutical compns. thereof are particularly well suited for activation and subsequent inhibition of the IMPDH enzyme activity. The rate of absorption of I via oral uptake of the prodrugs was dependent on the nature of substituents Z and Y, as well as the pH, with AUC values ranging from <1 to 5 mg.cntdot.hr/mL. Consequently, I may be advantageously used as therapeutic agents for IMPDH-mediated processes, e.g., cell preliferation (antitumor agents), and viral replication (antiviral agents).

IT 317345-64-5P 317345-66-7P 317345-68-9P 317345-70-3P 317345-72-5P 317345-74-7P 317345-76-9P

RL: BAC (Biological activity or effector, except adverse); BPR (Biological $\,$

process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL
(Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (prepn. and biol. activity of N,N'-diphenylurea prodrugs of carbamate inhibitors of IMPDH)

RN 317345-64-5 CAPLUS


CN Carbamic acid,

Absolute stereochemistry.

HCl

RN 317345-66-7 CAPLUS

CN Carbamic acid, (4-amino-1-oxobutyl)[[3-[[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]phenyl]methyl]-, (3S)-tetrahydro-3-furanyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 317345-68-9 CAPLUS

CN Glycinamide, N-methylglycyl-N-[[3-[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]phenyl]methyl]-N2-methyl-N-[[[(3S)-tetrahydro-3-furanyl]oxy]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

● HCl

RN 317345-70-3 CAPLUS

CN Carbamic acid,

[3,3-dimethyl-4-(methylamino)-1-oxobutyl][[3-[[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]phenyl]methyl]-,
(3S)-tetrahydro-3-furanyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 317345-72-5 CAPLUS CN L-Prolinamide, L-prolyl-N-[[3-[[[[3-methoxy-4-(5-

oxazolyl)phenyl]amino]carbonyl]amino]phenyl]methyl]-N-[[[(3S)-tetrahydro-3furanyl]oxy]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

RN 317345-74-7 CAPLUS
CN L-Prolinamide, N-methylglycyl-N-[[3-[[[3-methoxy-4-(5-

oxazolyl)phenyl]amino]carbonyl]amino]phenyl]methyl]-N-[[[(3S)-tetrahydro-3furanyl]oxy]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

S Ν 0 ΗN Ν 0 NHMe MeO N H 0 0 0 0 0 S R

HCl

RN 317345-76-9 CAPLUS
CN L-Glutamine,
N-[[3-[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]carbonyl]amino
]phenyl]methyl]-N-[[[(3S)-tetrahydro-3-furanyl]oxy]carbonyl]-,
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● HCl

IT 317345-62-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and biol. activity of N,N'-diphenylurea prodrugs of carbamate inhibitors of IMPDH)

RN 317345-62-3 CAPLUS

CN Carbamic acid, [4-[[(1,1-dimethylethoxy)carbonyl]methylamino]-1-

oxobutyl][[3-[[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]pheny l]methyl]-, (3S)-tetrahydro-3-furanyl ester (9CI) (CA INDEX NAME)

Ме

0

N OBu-t 0

0 (CH₂)₃

NΗ MeO

> Ν S Η

0

REFERENCE COUNT:

REFERENCE(S):

1988,

(1) Beylin, V; JOURNAL OF HETEROCYCLIC CHEMISTRY

V25(1), P97 CAPLUS

(2) Kahns, A; 1991, 6, P483 CAPLUS

(3) Kahns, A; INT J PHARM 1991, V71(1-2), P31 CAPLUS

(4) Sharma, S; JOURNAL OF MEDICINAL CHEMISTRY 1989,

V32(2), P357 CAPLUS

(5) Vertex Pharmaceuticals Incorporated; WO 9740028 A

1997 CAPLUS

ANSWER 3 OF 6 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:

2000:351518 CAPLUS

DOCUMENT NUMBER:

133:4650

TITLE:

Preparation of heteroaryl-substituted aromatic

compounds as antiherpes compounds

INVENTOR(S):

Simoneau, Bruno; Crute, James J.; Faucher,

Anne-Marie;

Grygon, Christine A.; Hargrave, Karl D.; Thavonekham,

Bounkham

PATENT ASSIGNEE(S):

Boehringer Ingelheim (Canada) Ltd., Can.

SOURCE:

PCT Int. Appl., 157 pp. CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

APPLICATION NO. DATE PATENT NO. KIND DATE ---------_____ WO 2000029399 A1 20000525 WO 1999-CA1066 19991109

W: CA, JP, MX, US

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,

PT, SE PRIORITY APPLN. INFO.:

US 1998-108272 P 19981112

OTHER SOURCE(S): MARPAT 133:4650

GΙ

- The title compds. X-Aryl-Y-Z [I; X = 5-6 membered arom. heterocycle; Aryl = (un)substituted Ph, pyridyl; Y is absent or a bridging group, for example NHC(O)CH2; Z is a terminal group, for example NHCO2t-Bu or II], which inhibit the herpes helicase-primase enzyme, rendering the compds. useful as antiviral agents, were prepd. E.g., a multi-step synthesis of benzamide III was presented. Biol. data (IC50 and/or EC50 against HSV-1 and HCMV) for compds. I were given.
 - 270566-02-4P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heteroaryl-substituted arom. compds. as antiherpes compds.) RN 270566-02-4 CAPLUS

CN Benzamide,

N-[2-[[4-(5-oxazolyl)phenyl]amino]-2-oxoethyl]-N-(phenylmethyl)(9CI) (CA INDEX NAME)

REFERENCE COUNT: REFERENCE(S): 5

- (1) Boehringer Ingelheim Ca Ltd; WO 9724343 A 1997 CAPLUS
- (2) Ciba Geigy Ag; EP 0045081 A 1982 CAPLUS

(3) Sanofi Sa; FR 2754258 A 1998 CAPLUS

- (4) Spector, F; JOURNAL OF VIROLOGY 1998, V72(9), P6979 CAPLUS
- (5) Tularik Inc; WO 9942455 A 1999 CAPLUS

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2000:314682 CAPLUS

DOCUMENT NUMBER:

132:334449

TITLE:

Preparation of N-[4-(5-oxazolyl)phenyl] amides as novel inhibitors of IMPDH enzyme

INVENTOR(S): Gu, Henry H.; Dhar, T. G. Muralı; Iwanowicz, Edwin

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DOCUMENT TYPE: LANGUAGE: Patent English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. APPLICATION NO. DATE KIND DATE 20000511 WG 1999-US24889 19991022 -----WO 2000026197 A1 W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KM, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UE, VN, YU, ZA, ZW, AM, AZ, BY, KG, KE, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG EP 1127054 A1 20010829 EP 1999-960145 19991022 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO US 1998-106180 P 19981029 PRIORITY APPLN. INFO.: WO 1999-US24889 W 19991022 MARPAT 132:334449 OTHER SOURCE(S):

AB The title compds. ZJKLX [I; Z = (un) substituted monocyclic or bicyclic ring system contg. up to 4 heteroatoms selected from N, O, and S; J = NR7,

CO; K = NR7, CO, CHR9; L = a single bond, CO, CR10R11, etc.; X = alkyl, alkenyl, cycloalkylalkyl, etc.; R7 = H, alkyl, alkenyl, etc.; R9 = H, alkyl, alkenyl, etc.; R10, R11 = H, F, Cl, etc.], useful in treating or preventing IMPDH assocd. disorders, such as transplant rejection and autoimmune disease, were prepd. E.g., a multi-step synthesis of gycinamide II was given. Compds. I are effective at 0.1-500 mg/kg/day.

IT 267405-70-9P 267405-71-0P 267405-72-1P 267405-73-2P 267405-74-3P 267405-75-4P 267405-79-8P 267405-86-7P 267405-87-8P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-[4-(5-oxazolyl)phenyl] amides as novel inhibitors of

IMPDH

GΙ

enzyme)

RN 267405-70-9 CAPLUS

CN Ethanediamide,

N-[1,1-dimethyl-2-oxo-2-(1-piperidinyl)ethyl]-N'-[3-methoxy-1]

PAGE 1-A

Ν

•

NH

C 0

C=--- O

NH

Me-C-Me

C = 0

PAGE 2-A

N_\

RN 267405-71-0 CAPLUS

CN Ethanediamide, N-[1,1-dimethyl-2-(4-methyl-1-piperazinyl)-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)

0 .

NH

C -- 0

C ' = 0

NH

Me-C Me

C -- -- O

PAGE 2-A



Ме

RN 267405-72-1 CAPLUS CN Ethanediamide,

N-[1,1-dimethyl-2-(4-morpholinyl)-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)

ИИ

C 1 0

C -- 0

ИН

Me-C Me

C---= 0

PAGE 2-A

, o

RN 267405-73-2 CAPLUS

CN

1-Piperazinecarboxylic acid, 4-[N-[3-methoxy-4-(5-oxazolyl)phenyl]-2-oxoglycyl-2-methylalanyl]-, ethyl ester (9CI) (CA INDEX NAME)

O MeO

NH

C =- 0

C ==== 0

ΝН

 $\mathrm{Me}^{-1}\,\mathrm{C-Me}$

c = 0

PAGE 2-A

N N EtO C

RN 267405-74-3 CAPLUS

CN Ethanediamide,

 $\begin{tabular}{ll} N-[2-[3-(acetylmethylamino)-l-pyrrolidinyl]-l,l-dimethyl-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]-(9CI) & (CA INDEX NAME) \\ \end{tabular}$

0 0 Me 0 Me

NH-C-C-NH-C-C-N

Me

N-
Me

RN 267405-75-4 CAPLUS

CN Alaninamide,

N-[3-methoxy-4-(5-oxazolyl)phenyl]-2-oxoglycyl-N,2-dimethyl-N-[2-(methylamino)ethyl]- (9CI) (CA INDEX NAME) MeO

Me O Me O

MeNH CH2 CH2 N C C NH C C NH

Me O

RN 267405-79-8 CAPLUS

CN Alanınamide,

 $\begin{tabular}{ll} N-[3-methoxy-4-(5-oxazolyl)phenyl]-2-oxoglycyl-2-methyl-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-(9CI) & (CA INDEX NAME) \end{tabular}$

0 0 Me 0

Me0

O NH-C C NH-C-C-NH-(CH₂)3--N

Me

RN 267405-86-7 CAPLUS

CN Alaninamide, N-[3-methoxy-4-(5-oxazolyl)phenyl]-2-oxoglycyl-N,N,2-trimethyl- (9CI) (CA INDEX NAME)

0 Me 0
Me2N C-C-NH-C-C-NH
Me 0

RN 267405-87-8 CAPLUS

CN Ethanediamide, N-[2-[4-(2-methoxyethyl)-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)

0 ...

MeO

ИН

C -= 0

 $C \rightarrow -0$

NH

Me - C - Me

C==== 0

PAGE 2-A

N Λ.

CH2- CH2- OMe

REFERENCE COUNT:

REFERENCE(S): (1) Diana; US 4861791 A 1989 CAPLUS

3

(2) Djuric; US 5073562 A 1991 CAPLUS

(3) Goldstein; US 5334604 A 1994 CAPLUS

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:

2000:268526 CAPLUS

DOCUMENT NUMBER:

132:288797

TITLE:

Inosine 5'-monophosphate dehydrogenase (IMPDH)

inhibitor preparation for therapeutic use

INVENTOR(S):

Armistead, David M.; Badia, Michael C.; Bemis, Guy

W.;

Bethiel, Randy S.; Frank, Catharine A.; Novak, Perry

M.; Ronkin, Steven M.; Saunders, Jeffrey O. Vertex Pharmaceuticals, Incorporated, USA

PATENT ASSIGNEE(S): SOURCE:

U.S., 22 pp., Cont.-in-part of U.S. 5,807,876. CODEN: USXXAM

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

```
20000425
19980915
19971030
                                20000425
                                                                     19970402
     US 6054472
                         А
                                                  US 1997-832165
     US 5807876
                                                  US 1996-636361
                         А
                                                                      19960423
     WO 9740028
                         A1
                                                 WO 1997-US6623
                                                                     19970421
          W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
               DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
          RW: GH, KE, LS, MW, SD, SI, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN,
               ML, MR, NE, SN, TD, TG
                                                  AU 1997-26785
                                                                      19970421
     AU 9726785
                        A1 19971112
     AU 723730
                                20000907
                          В2
                               19990324
                                                 EP 1997-918759 19970421
     EP 902782
                          Α1
          H: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
               IE, SI, LT, LV, FI, RO
                                                  CN 1997-194856 19970421
     CN 1219929
                        A 19990616
                                                 BR 1997-8735
                                                                      19970421
     BR 9708735
                                19990803
                          Α
                         T2 20010710
     JP 2001509132
                                                  JP 1997-538234 19970421
                        A 19981223
A 20000215
                                                  NO 1998-4917
                                                                     19981022
     NO 9804917
     KR 2000010580
                                                 KR 1998-708454 19981022
PRIORITY APPLN. INFO.:
                                               US 1996-636361 A2 19960423
                                               US 1997-801780 A2 19970214
                                               US 1997-832165 A 19970402
                                               WO 1997-US6623 W 19970421
```

OTHER SOURCE(S): MARPAT 132:288797

AB The invention relates to a novel class of compds. which are IMPDH inhibitors. This invention also relates to pharmaceutical compns. comprising these compds. The compds. and pharmaceutical compns. of the invention are particularly well suited for inhibiting IMPDH activity and consequently may be used as therapeutic agents for IMPDH-mediated processes. The invention also relates to methods for inhibiting the activity of IMPDH using the compds. of the invention and related compds.

IT 198821-00-0P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(inosine monophosphate dehydrogenase inhibitor prepn. for therapeutic use)

RN 198821-00-0 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[3-[[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

0 MeO

NH

C 0

NH

N-C-CF3

Me O

IT 198820-96-1 198821-11-3

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (inosine monophosphate dehydrogenase inhibitor prepn. for therapeutic use)

RN 198820-96-1 CAPLUS

CN Acetamide,

N-[3-[[[[3-chloro-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]phenyl]-2,2,2-trifluoro-N-methyl- (9CI) (CA INDEX NAME)

O- 1

 ${\tt Cl}$

**.../

NH

c== 0

NH

N-C-CF3

RN 198821-11-3 CAPLUS

CN Acetamide,

N-[3-[[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

MeO

NH

C -0

NH

N-- Ac

Me

REFERENCE COUNT:

13

REFERENCE(S):

- (1) Anon; US 4048333 1977 CAPLUS (2) Anon; WO 3401105 1994 CAPLUS
- (3) Anon; WO 9412184 1994 CAPLUS (4) Anon; US 5380879 1995 CAPLUS (5) Anon; US 5444072 1995 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 6 OF 6 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:

1997:717901 CAPLUS

DOCUMENT NUMBER:

128:3680

TITLE:

Preparation of arylreas and related compounds as

inhibitors of inosine 5'-monophosphate dehydrogenase. Armistead, David M.; Badia, Michael C.; Bemis, Guy

INVENTOR(S):

W.;

Bethiel, Randy S.; Frank, Catharine A.; Novak, Perry

M.; Ronkin, Steven M.; Saunders, Jeffrey O.

PATENT ASSIGNEE(S):

SOURCE:

Vertex Pharmaceuticals Inc., USA

PCT Int. Appl., 93 pp.

CODEN: PIXXD2

DOCUMENT TYPE: LANGUAGE:

Patent English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PAT	TENT	ΝΟ.		KI	ND	DATE			A	PPLI	CATI	и ис	0.	DATE			
WO	9740	028		A	1	1997	1030		W	0 19	97-U	s662	3	1997	0421		
	W:	AL,	AM,	AT,	ΑU,	AZ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CU,	CZ,	DE,
		DK,	EE,	ES,	FI,	GB,	GE,	GH,	HU,	IL,	IS,	JP,	ΚE,	KG,	ΚP,	KR,	ΚZ,
		LC,	LK,	LR,	LS,	LT,	LU,	LV,	MD,	MG,	MK,	MN,	MW,	MX,	NO,	NΖ,	PL,
		PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	ТJ,	TM,	TR,	TT,	UA,	UG,	UZ,	VN,
		YU,	AM,	AZ,	BY,	KG,	KΞ,	MD,	RU,	ТJ,	TM						
	RW:	GH,	KE,	LS,	MW,	SD,	SZ,	UG,	AT,	BE,	CH,	DE,	DK,	ES,	FΙ,	FR,	GB,
		GR,	ΙE,	ΙΤ,	LU,	MC,	NL,	PT,	SE,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,
		ML,	MR,	ΝE,	SN,	TD,	TG										
US	5807	876		А		1998	0915		U.	5 19	96-6	3636	1	19960	0423		
US	6054	472		А		2000	0425		U:	s 19	97-8	3216	5	19970	0402		
ΑU	9726	785		A.	1	1997	1112		A	J 19	97-2	6785		19970	0421		
ΑU	7237	30		В	2	2000	0907										
ΕP	9027	82		A.	1	1999	0324		E	P 19	97-9	1875	9	1997	0421		
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	ΙΤ,	LI,	LU,	NL,	SE,	MC,	PT,

0

```
IE, SI, LT, LV, FI, RO
     BR 9708735 A 19990803
                                          BR 1997-8735
                                                           19970421
                     T2
                                          JP 1997-538234
     JP 2001509132
                           20010710
                                                            19970421
    NO 9304917
                            19981223
                                          NO 1998-4917
                                                            19981022
                      A
                                        US 1996-636361 A 19960423
US 1997-801780 A 19970214
PRIORITY APPLN. INFO.:
                                        US 1997-832165 A 19970402
                                        WO 1997-US6623 W 19970421
                        MARPAT 128:3680
OTHER SOURCE(S):
    ANHDNHB [A = (substituted) alkyl, alkenyl, alkynyl; B = (unsatd.)
     (substituted) mono- or bicyclic ring contg. .ltoreq.4 heteroatoms; D =
CO,
     CS, SO2], were prepd. Thus, 4-(5-oxazolyl)aniline and PhCH2NCO were
     stirred overnight in CH2Cl2 to give N-benzyl-N'-[4-(5-
    oxazolyl)phenyl]urea. Several title compds. inhibited IMPDH with Ki =
    0.01-50 nM.
    198821-00-0P
ΙT
    RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic
    preparation); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); USES (Uses)
        (prepn. of arylreas and related compds. as inhibitors of IMP
       dehydrogenase)
RN
    198821-00-0 CAPLUS
CN
    Acetamide, 2,2,2-trifluoro-N-[3-[[[3-methoxy-4-(5-
    oxazolyl)phenyl]amino]carbonyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX
```



IT 198820-96-1 198821-11-3

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (prepn. of arylreas and related compds. as inhibitors of IMP dehydrogenase)

RN 198820-96-1 CAPLUS
CN Acetamide,
N-[3-[[[[3-chloro-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]phe nyl]-2,2,2-trifluoro-N-methyl- (9CI) (CA INDEX NAME)

0

Cl

NH

ΝН

N-C-CF3

Me O

RN 198821-11-3 CAPLUS

CN Acetamide,

N-[3-[[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

N.

MeO I

NH

NH N- Ac

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	40.79	181.48
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.58	-5.58

STN INTERNATIONAL LOGOFF AT 10:31:09 ON 15 JAN 2002